Diagnosis & Follow up of Bladder Cancer

Accroche

VisioCyt® allows an earlier diagnosis of bladder cancer from a simple urine sample. 

This innovative solution is based on a patented technology combining  imaging and artificial intelligence. 

VisioCyt®, validated by a clinical multicentric prospective trial, is CE marked (in accordance with directive 98/78 CE).

Technology
Infographie
Image
Inforgraphie EN
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Image de fond
Image
banner
Clinical
Texte

In 2017, VitaDX launched a large clinical trial, named VisioCyt1, on 1,360 patients recruited from 14 hospitals throughout France: the Foch Hospital, Cochin, CHP Antony, CHU Rennes, CHU Clermont Ferrand, HCL Lyon, Clinique Chataigneraie, CH Toulouse, the Paoli-Calmettes Institute in Marseille, CHU Nancy, CH Nantes, CH Nîmes, CH Besançon, Clinique Beausoleil Montpellier.

The results of this multicentric study, finalized in January 2021, confirmed the effectiveness of the deployed solution with an overall sensitivity of over 81% (much higher than that of conventional urinary cytology with a 45% sensitivity), 66.7% versus 25.4% for low grades and finally, 93.7% versus 61.3% for high grades.

 

 

Image
clinique
About us
Texte

Founded in 2015 to exploit patented work from French institutional research, conducted by researchers from the Institute of Molecular Sciences of Orsay (ISMO, UMR CNRS and University of Paris-Sud) and practitioners from the CHU Bicêtre (AP-HP), VitaDX, a deep tech based in Rennes and Paris, develops and markets cancer diagnostic solutions combining artificial intelligence and image processing applied to cytology.

The company's mission is to develop innovative cancer diagnostic solutions that are more efficient, more reliable and have a significant impact on medical and economic systems to  benefit the greatest number of patients.

 

Image
VitaDx
News
Dernières actualités
VitaDX
Come and meet us !
2 January 2023 - News

We will be present at several events in 2023. If you'd like to find out more about us and VisioCyt, our first innovative solution for bladder…

masterclass
Mltidisciplinary Masterclass dedicated to prostate and bladder cancers
8 July 2022 - News

Multidisciplinary Masterclass organized by the American Hospital in Paris, MEDIPATH and Ibex Medical Analytics dedicated to prostate and bladder…

Medipath
VitaDX and MEDIPATH collaborate to deploy VisioCyt® , an innovative solution for the early diagnosis of bladder cancer
6 July 2022 - Publishing

VitaDX is proud to announce its partnership with Medipath, a group of independant pathologists specialized in locally based diagnostics and…

Image de fond
Image
banner
Contact
Nom commercial
VisioCyt / VitaDX International
Numéro de téléphone
+33(0)148 87 00 55
74F, rue de Paris
35000 Rennes, France
28 rue de Chambéry
75015 Paris, France
Formulaire
Image CAPTCHA
Enter the characters shown in the image.